1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Reyon Pharmaceutical Co., Ltd.

Reyon Pharmaceutical Co., Ltd.

KKRX:102460
9,900.00
KRW
-20.00
(-0.20%)
-1,867.12EPS
186.34BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,409.69
6,556.35
6,694.9
7,265.79
7,376.57
7,273.02
7,640.3
7,644.24
7,865.71
8,599.52
8,220.99
8,073.67
7,958.01
7,817.23
Basic EPS, GAAP
659.88
677.98
662.9
638.13
752.94
79.41
287.25
226
305
415
195
226
-1,616
-1,867.12
Free Cash Flow per Basic Share
-257.28
546.59
470.59
373.16
705.58
-1,653.84
-3,691.51
-2,804.89
-5,800.75
-3,037.21
-1,100.73
-950.47
-352.22
64.21
Dividend per Share
- -
- -
188.56
230.77
263.8
347.07
479.93
340.06
190.81
254.75
148.99
149.78
- -
- -
Book Value per Share
8,207.58
9,091.04
12,734.47
10,470.1
12,842.8
13,258.86
13,002.7
13,284.4
13,799.95
13,942.36
13,555.68
13,627.46
12,009.87
10,624.82
Tangible Book Value per Share
7,450.05
8,219.39
11,644.33
10,203.47
12,575.92
12,989.61
12,724.32
13,039.46
13,561.87
13,705.55
13,327.13
13,376.49
11,776.51
10,435.83
Basic Weighted Avg Shares
17
17
17
17
17
17
17
17
18
18
18
18
18
18
Sales/Revenue/Turnover
109,693
112,112
114,507
121,847
126,253
122,990
131,558
130,034
142,801
154,039
151,071
148,300
145,929
143,375
Operating Margin (%)
15.89
14.92
17.32
11.54
12.67
2
5.03
2.65
2.13
6.05
2.04
-0.37
-21.03
-20.52
Depreciation Expense
2,397
1,855
1,760
1,942
2,005
1,867
4,088
4,565
4,666
4,534
4,782
6,344
31,794
31,952
Net Income, GAAP
11,293
11,593
11,338
10,701
12,887
1,343
4,946
3,844
5,537
7,434
3,583
4,151
-29,633
-34,245
Effective Tax Rate (%)
38.19
23.18
45
22.09
21.21
- -
24.6
11.98
5.26
- -
11.13
19.6
- -
- -
Profit Margin (%)
10.3
10.34
9.9
8.78
10.21
1.09
3.76
2.96
3.88
4.83
2.37
2.8
-20.31
-23.88
Working Capital
86,737
95,468
99,351
98,080
146,214
181,916
97,274
69,020
117,301
61,055
-25,789
-46,093
-63,666
-79,808
LT Debt
- -
- -
- -
- -
34,040
35,269
19,156
36,444
182,903
185,449
122,788
113,393
99,699
90,009
Total Equity
140,394
155,506
217,828
179,095
219,664
225,392
221,296
230,089
245,237
247,765
248,625
249,941
220,273
194,870
Return on Invested Capital (%)
7.26
7.83
5.62
5.5
5.86
- -
1.87
1.36
0.97
- -
0.78
0.01
- -
- -
Return on Capital (%)
7.54
7.01
5.81
5.34
6.03
- -
1.95
1.47
1.52
- -
0.81
1.11
- -
- -
Return on Common Equity (%)
8.47
7.84
6.07
5.39
6.46
0.61
2.23
1.71
2.33
3.02
1.44
1.67
-12.6
-15.86

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
116,416
123,582
126,844
LT Borrowings
99,000
95,000
89,500
LT Finance Leases
699
591
509
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
197,716
184,144
186,344

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
79,665
76,786
78,542
Cash, Cash Equivalents & STI
6,782
4,351
7,036
Accounts Receivable, Net
34,381
35,463
34,076
Inventories
37,930
36,466
36,683
Total Current Liabilities
143,331
147,831
158,350
Payables & Accruals
- -
- -
- -
ST Debt
116,416
123,582
126,844
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.63%
-0.68%
-11.87%
Free Cash Flow
-22.56%
-13.43%
-63%
Net Income, GAAP
-60.02%
-154.3%
-813.84%
Sales/Revenue/Turnover
2.56%
2.47%
-1.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37,015
35,681
38,293
37,311
148,300
2025
36,758
37,692
37,582
33,896
145,929
2026
36,051
35,845
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18
36
34
138.82
226
2025
12
-717
-210.59
-700.11
-1,616
2026
-585.41
-371
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
149.78
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Soon-Ock Jung
Full Time Employees
457
Sector
Health technology
Industry
Pharmaceuticals: major
Address
416 Yeongdong-daero Seoul SL South Korea
IPO Date
Jun 10, 2010
Website
reyonpharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
REYON Pharmaceutical Co., Ltd. (102460.KS) manufactures and markets active pharmaceutical ingredients (APIs), generic finished dosage formulations and contrast agents for the pharmaceutical industry. The company produces over 40 high-value APIs through organic synthesis and fermentation technologies accumulated over 60 years, including Arbekacin sulfate (ABK), Streptokinase/Streptodornase (SKD), antibiotics, antiphlogistics and adrenal corticosteroides; it offers 310 registered generic medicines in various forms such as injections (e.g., Alprodex Inj., Vecaron Inj., Rocaine Inj., Toburex Inj.), tablets (e.g., Carbi XL SR Tab.), capsules (e.g., Tacroli Cap.) and others addressing aging society needs; and markets the OptiRay series of contrast agents for diagnostic imaging, achieving significant domestic sales. Reyon Pharmaceutical operates from headquarters at 12F, Building A, Mirae Asset Tower, 620 Teheran-ro, Gangnam-gu, Seoul, South Korea, with manufacturing facilities including a KGMP- and PMDA-certified plant in Jincheon-gun, Chungcheongbuk-do; founded in 1955, it exports products to countries including Vietnam, Malaysia, Mongolia, Peru and Turkey while expanding into biopharmaceuticals such as AAV gene therapy for wet age-related macular degeneration (wAMD, NG101 in phase 1/2a trials in Canada since 2023), NK cell therapy for solid cancers (TB-100, joint development with Therabest) and biopharma CDMO services. Recent developments include joint development agreements with Neuracle Genetics for gene therapy (2020, exclusive worldwide rights) and Therabest for NK cell therapy (April 2023); MOUs for CDMO expansion with Protium Science and Connext (December 2022); and ongoing advancements in cell/gene therapies and global market penetration.